Quốc gia: Liên Minh Châu Âu
Ngôn ngữ: Tiếng Malt
Nguồn: EMA (European Medicines Agency)
Isatuximab
Sanofi Winthrop Industrie
L01XC38
isatuximab
Aġenti antineoplastiċi
Majloma Multipla
Sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (PI) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.
Revision: 8
Awtorizzat
2020-05-30
The website encountered an unexpected error. Try again later.
Đọc toàn bộ tài liệu
The website encountered an unexpected error. Try again later.
Đọc toàn bộ tài liệu